vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and SITIME Corp (SITM). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $113.6M, roughly 1.6× SITIME Corp). On growth, SITIME Corp posted the faster year-over-year revenue change (88.3% vs 0.7%). Over the past eight quarters, SITIME Corp's revenue compounded faster (60.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
AVNS vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $113.6M |
| Net Profit | $-1.3M | — |
| Gross Margin | 47.5% | 59.0% |
| Operating Margin | 1.4% | 30.2% |
| Net Margin | -0.7% | — |
| Revenue YoY | 0.7% | 88.3% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.6M | ||
| Q4 25 | $180.9M | $113.3M | ||
| Q3 25 | $177.8M | $83.6M | ||
| Q2 25 | $175.0M | $69.5M | ||
| Q1 25 | $167.5M | $60.3M | ||
| Q4 24 | $179.6M | $68.1M | ||
| Q3 24 | $170.4M | $57.7M | ||
| Q2 24 | $171.7M | $43.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.3M | $9.2M | ||
| Q3 25 | $-1.4M | $-8.0M | ||
| Q2 25 | $-76.8M | $-20.2M | ||
| Q1 25 | $6.6M | $-23.9M | ||
| Q4 24 | $-397.3M | $-18.8M | ||
| Q3 24 | $4.3M | $-19.3M | ||
| Q2 24 | $1.8M | $-26.8M |
| Q1 26 | — | 59.0% | ||
| Q4 25 | 47.5% | 56.4% | ||
| Q3 25 | 48.4% | 53.5% | ||
| Q2 25 | 52.6% | 51.9% | ||
| Q1 25 | 53.6% | 50.3% | ||
| Q4 24 | 54.6% | 52.6% | ||
| Q3 24 | 54.5% | 51.1% | ||
| Q2 24 | 55.7% | 49.1% |
| Q1 26 | — | 30.2% | ||
| Q4 25 | 1.4% | 1.6% | ||
| Q3 25 | 0.1% | -19.2% | ||
| Q2 25 | -42.6% | -35.4% | ||
| Q1 25 | 6.1% | -46.6% | ||
| Q4 24 | -233.0% | -33.8% | ||
| Q3 24 | 7.0% | -43.1% | ||
| Q2 24 | 3.7% | -73.7% |
| Q1 26 | — | — | ||
| Q4 25 | -0.7% | 8.1% | ||
| Q3 25 | -0.8% | -9.6% | ||
| Q2 25 | -43.9% | -29.0% | ||
| Q1 25 | 3.9% | -39.6% | ||
| Q4 24 | -221.2% | -27.6% | ||
| Q3 24 | 2.5% | -33.5% | ||
| Q2 24 | 1.0% | -61.0% |
| Q1 26 | — | $-0.20 | ||
| Q4 25 | $-0.02 | $0.44 | ||
| Q3 25 | $-0.03 | $-0.31 | ||
| Q2 25 | $-1.66 | $-0.84 | ||
| Q1 25 | $0.14 | $-1.01 | ||
| Q4 24 | $-8.64 | $-0.80 | ||
| Q3 24 | $0.09 | $-0.83 | ||
| Q2 24 | $0.04 | $-1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $498.5M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.2B |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $498.5M | ||
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $778.2M | $1.2B | ||
| Q3 25 | $778.0M | $1.1B | ||
| Q2 25 | $776.3M | $1.1B | ||
| Q1 25 | $839.4M | $692.5M | ||
| Q4 24 | $828.5M | $699.7M | ||
| Q3 24 | $1.2B | $696.2M | ||
| Q2 24 | $1.2B | $692.5M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.1B | $872.1M | ||
| Q4 24 | $1.2B | $885.0M | ||
| Q3 24 | $1.7B | $877.9M | ||
| Q2 24 | $1.7B | $878.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $25.4M | ||
| Q3 25 | $14.0M | $31.4M | ||
| Q2 25 | $6.8M | $15.3M | ||
| Q1 25 | $25.7M | $15.0M | ||
| Q4 24 | $57.9M | $13.5M | ||
| Q3 24 | $23.0M | $8.2M | ||
| Q2 24 | $27.8M | $-181.0K |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $13.0M | ||
| Q3 25 | $7.0M | $26.3M | ||
| Q2 25 | $-4.2M | $-2.9M | ||
| Q1 25 | $19.0M | $-1.3M | ||
| Q4 24 | $53.1M | $-2.4M | ||
| Q3 24 | $20.0M | $-6.7M | ||
| Q2 24 | $21.9M | $-2.7M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 11.5% | ||
| Q3 25 | 3.9% | 31.5% | ||
| Q2 25 | -2.4% | -4.2% | ||
| Q1 25 | 11.3% | -2.1% | ||
| Q4 24 | 29.6% | -3.5% | ||
| Q3 24 | 11.7% | -11.6% | ||
| Q2 24 | 12.8% | -6.3% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 10.9% | ||
| Q3 25 | 3.9% | 6.1% | ||
| Q2 25 | 6.3% | 26.2% | ||
| Q1 25 | 4.0% | 27.0% | ||
| Q4 24 | 2.7% | 23.3% | ||
| Q3 24 | 1.8% | 25.7% | ||
| Q2 24 | 3.4% | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SITM
Segment breakdown not available.
